Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Drug Safety Clear all
Completed Phase 4 Interventional Results available

Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy

NCT04319198
View directory record Official record
Conditions
Metastatic Solid Tumors
Interventions
Sacituzumab Govitecan-hiy
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
16
States / cities
San Francisco, California • Aurora, Colorado • Newark, Delaware + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 2 Interventional

Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

NCT06272487
View directory record Official record
Conditions
High Cardiovascular Risk, Hypertension
Interventions
Zilebesiran, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
139
States / cities
Alexander City, Alabama • Daphne, Alabama • Foley, Alabama + 115 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 1 Interventional

Safety of Interleukin-7 in HIV Infected People Currently Taking Anti-HIV Drugs

NCT00099671
View directory record Official record
Conditions
HIV Infections
Interventions
Recombinant human interleukin-7
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Sacramento, California • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 17, 2026, 4:42 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of ZW191 in Participants With Solid Tumors

NCT06555744
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ZW191
Drug
Lead sponsor
Zymeworks BC Inc.
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
New Haven, Connecticut • Columbus, Ohio • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)

NCT02193087
View directory record Official record
Conditions
Dengue Fever
Interventions
TDV Liquid Formulation 1, TDV Liquid Formulation 2, TDV IDT Lyophilized, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,002 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
7
States / cities
Phoenix, Arizona • Anaheim, California • Stockbridge, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents

NCT00488514
View directory record Official record
Conditions
Migraine Disorders
Interventions
Combination Tablet of Treximet (sumatriptan/naproxen sodium)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 17 Years
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
77
States / cities
Gilbert, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 72 more
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of TAK-279 in Adults With or Without Liver Damage

NCT05976321
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
TAK-279
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Results available

A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma

NCT00413036
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin's
Interventions
lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Muscle Shoals, Alabama • Scottsdale, Arizona • Fountain Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients

NCT00002234
View directory record Official record
Conditions
HIV Infections
Interventions
Efavirenz, Adefovir dipivoxil, Lamivudine, Didanosine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 17, 2026, 4:42 AM EDT
Recruiting Phase 1 Interventional

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

NCT05372614
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Malignant Solid Neoplasm, Unresectable Pancreatic Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Neratinib Maleate, Trastuzumab Deruxtecan
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
18
States / cities
Duarte, California • Irvine, California • Lancaster, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 2Phase 3 Interventional

Familiarization and Safety Study of PB127 Ultrasound Contrast Agent

NCT00594698
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PB127 for injectable suspension
Drug
Lead sponsor
Point Biomedical
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
34
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Long Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2008 · Synced Sep 17, 2026, 4:42 AM EDT
Terminated Phase 3 Interventional

Extended Management and Measurement of Autism

NCT00787111
View directory record Official record
Conditions
Autistic Disorder
Interventions
Fluoxetine (prozac)
Drug
Lead sponsor
Neuropharm
Industry
Eligibility
5 Years to 18 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
13
States / cities
Phoenix, Arizona • Sacramento, California • Smyrna, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2010 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 3 Interventional Results available

Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder

NCT02318602
View directory record Official record
Conditions
Seizures
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
1 Year to 18 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
San Francisco, California • Miami, Florida • Pensacola, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Loss of Liver Function Affects the Blood Levels of the Study Medicine Called PF-07817883.

NCT05884554
View directory record Official record
Conditions
COVID-19
Interventions
PF-07817883
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
6
States / cities
Anaheim, California • Garden Grove, California • Montclair, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 17, 2026, 4:42 AM EDT
Terminated Phase 1 Interventional

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT04682431
View directory record Official record
Conditions
Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Lung Adenocarcinoma, Pancreatic Cancer, Head and Neck Cancer
Interventions
PY159 Single agent dose level 1, PY159 Single agent dose level 2, PY159 Single agent dose level 3, PY159 Single agent dose level 4, PY159 Single agent dose level 5, PY159 Single agent dose level 6, PY159 Single agent dose level 7, PY159/Pembrolizumab Combination dose level 1, PY159/Pembrolizumab Combination dose level 2, PY159/Pembrolizumab Combination dose level 3, PY159/Pembrolizumab Combination dose level 4, PY159 Single agent dose expansion cohort, PY159/Pembrolizumab Combination dose expansion cohort 1, PY159/Pembrolizumab Combination dose expansion cohort 2, PY159/Pembrolizumab Combination dose expansion cohort 3, PY159/Pembrolizumab Combination dose expansion cohort 4, PY159/Pembrolizumab Combination dose expansion cohort 5, PY159/Pembrolizumab Combination dose expansion cohort 6
Drug
Lead sponsor
Ikena Oncology
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 17, 2026, 4:42 AM EDT
Terminated Phase 1 Interventional

A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.

NCT06546553
View directory record Official record
Conditions
Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Interventions
PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
Drug · Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Beverly Hills, California • Fort Myers, Florida • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs

NCT00002379
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Levocarnitine, Adefovir dipivoxil, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 3 Interventional Results available

A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

NCT04938427
View directory record Official record
Conditions
Lennox Gastaut Syndrome (LGS)
Interventions
Placebo, Soticlestat
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 55 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy

NCT02201251
View directory record Official record
Conditions
Epilepsy
Interventions
Topiramate, Levetiracetam
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 15 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Gulf Breeze, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 17, 2026, 4:42 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

NCT05932862
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
XL309, Olaparib
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
16
States / cities
Fountain Valley, California • Jacksonville, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simultaneous mRNA COVID-19 and IIV4 Vaccination Study

NCT05028361
View directory record Official record
Conditions
Quality of Life, Injection Site Reaction, Adverse Drug Event, Systemic Reaction
Interventions
mRNA COVID-19, IIV4, Placebo (saline)
Biological · Other
Lead sponsor
Duke University
Other
Eligibility
5 Years and older
Enrollment
348 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
Baltimore, Maryland • Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Results available

A Study of TAK-079 in People With Generalized Myasthenia Gravis

NCT04159805
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
TAK-079, TAK-079 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
27
States / cities
Tucson, Arizona • Palo Alto, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Sep 17, 2026, 4:42 AM EDT
Completed No phase listed Observational

Mycobacterium Avium Intracellulare Complex (MAC) Study

NCT00826423
View directory record Official record
Conditions
Mycobacterium Avium Intracellulare Complex (MAC)
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

NCT01711359
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Baricitinib, Methotrexate, Baricitinib Placebo, MTX Placebo, Folic Acid
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
47
States / cities
Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Sep 17, 2026, 4:42 AM EDT